Anti microRNA 92a inhibitor therapeutic - Causeway Therapeutics
Alternative Names: CardioMiRLatest Information Update: 27 Feb 2026
At a glance
- Originator Causeway Therapeutics
- Class Heart failure therapies; MicroRNAs
- Mechanism of Action MicroRNA inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Heart failure
Most Recent Events
- 11 Feb 2026 Preclinical trials in Heart failure in United Kingdom (unspecified route) (Causeway Therapeutics pipeline, February 2026)